ClinicalTrials.gg
CompletedNCT01670279Updated Feb 4, 2016Results posted

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

A Phase 1 interventional study of Brexpiprazole and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 4 sites in United States. Open to participants aged 70 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
70 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
21st of 24
18 · median 189
Started
2012
with 1 other
Phase 1
Only one
of the 24
Registered
6th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 21st largest by enrollment, is one of 2 that started in 2012, is the only one in phase 1, and was the 6th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 70 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.

Read the detailed description

This is a phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose trial in 3 sequential cohorts of elderly subjects (age 70 to 85 years old) with MDD. Brexpiprazole will be administered as an adjunct treatment to the current antidepressant therapy that the subject is receiving. Total individual subject duration is expected to be no more than 119 days (a 30-day screening period, a 14-day washout period, up to 45-day in-clinic treatment period, and a 30-day follow-up after the last dose of trial medication).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
70 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to provide written
  • Ability to understand the nature of the trial and follow protocol requirements
  • Male and female patients 70 to 85 years of age
  • Subjects with normal or clinically stable findings on physical examination, medical history, clinical laboratory determinations, ECGs in relation to age
  • of 18 to 35 kg/m2.
  • Stable subjects with a principal psychiatric diagnosis of MDD
  • Subjects willing to discontinue all prohibited psychotropic and other prohibited medication

Exclusion criteria

Exclusion Criteria:

  • Sexually active males who are not practicing 2 different methods of during the trial and for 30 days after the last dose of trial medication or who will not remain abstinent during the trial and for 30 days after the last dose
  • Subjects who have had a vagus nerve stimulation device implanted or who have received ECT within 6 months of Screening
  • Subjects with a current Axis I () diagnosis of:

    • Delirium, dementia, amnestic, or other cognitive disorder
    • Eating disorder (including anorexia nervosa or bulimia)
    • Obsessive-compulsive disorder
    • Panic disorder
    • Posttraumatic stress disorder or current or prior Axis I (DSM-IV-TR) diagnosis of Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder or bipolar disorder not otherwise specified
  • Subjects with a current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
  • Subjects experiencing hallucinations, delusions, or any psychotic symptomatology
  • Subjects who have Active Suicidal Ideation with Some Intent to Act and whose most recent episode occurred within the last 6 months
  • Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days
  • Subjects with hypothyroidism or hyperthyroidism and/or an abnormal result for free T4 at Screening
  • Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders
  • Subjects with IDDM
  • Subjects with uncontrolled hypertension (DBP > 95 mmHg) or symptomatic hypotension
  • Subjects with epilepsy, a history of epilepsy, or a history of seizure
  • Subjects with a positive drug screen for cocaine or other drugs of abuse
  • The following laboratory test and results are exclusionary:

    1. ≤ 75,000/mm3
    2. ≤ 9 g/dL
    3. Neutrophils, absolute ≤ 1000/mm3
    4. > 3 ×
    5. ALT > 3 × upper limit of normal
    6. Creatinine ≥ 2 mg/dL
    7. ≥ 7%
    8. ≥ 450 msec
  • Treatment with a MAOI within the 2 weeks prior to the first dose of trial medication
  • Use of benzodiazepines and/or hypnotics within 1 week prior the first dose of trial medication
  • Use of oral neuroleptics within 30 days prior to or long-acting approved neuroleptics ≤ 1 full cycle plus 14 days prior to the first dose of trial medication on Day 1
  • Prohibited concomitant medications used prior to randomization or anticipated need for such medications during the trial
  • Subjects who would be likely to require prohibited concomitant therapy during the trial
  • Subjects who received brexpiprazole in any prior clinical trial
  • Subjects with a history of neuroleptic malignant syndrome
  • Subjects with a history of true allergic response to more than 1 class of medications
  • Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
  • Subjects who participated in a clinical trial within the last 180 days or who participated in more than 2 clinical trials within the past year.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1

    14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.

    Drug: Brexpiprazole

  • Experimental
    Cohort 2

    14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.

    Drug: Brexpiprazole

  • Experimental
    Cohort 3

    21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.

    Drug: Brexpiprazole

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Tolerated Brexpiprazole

    Safety and tolerability of brexpiprazole was noted to be primary outcome measure. Brexpiprazole was judged to be tolerated if at least 6 out of 8 (75%) of the participants in a test cohort tolerated the dose after 14 days of QD dosing at the end of the fixed dose phase based on the blinded data. Dose toleration was defined as follows: during the course of the trial, the participants did not experience any moderate or severe adverse events (AEs) or potentially clinically relevant changes from Baseline in laboratory values, vital signs, electrocardiogram (ECG) tracings, Columbia-Suicide Severity Rating Scale (C-SSRS), or extrapyramidal symptom (EPS) ratings, which were assessed as possibly related to the study drug, and would have warranted a dose decrease or discontinuation of the study drug. The safety and tolerability of brexpiprazole was defined by parameters: AEs, laboratory values, vital signs, ECG, C-SSRS, or EPS ratings, the results of each of the parameters reported separately.

    Time frame: 45 Days

  2. Number of AEs Reported.

    The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial. AEs were measured throughout the 14-day titration and 28-day fixed dose phase until follow-up (30 \[±2\] days after last dose of study medication).

    Time frame: Throughout the study, up to 119 days

  3. Incidence of Laboratory Values of Potential Clinical Significance

    The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.

    Time frame: Titration Day 7, Fixed dose Day 14 and 28 and Last Visit

  4. Incidence of Vital Signs of Potential Clinical Significance

    The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.

    Time frame: Baseline, Titration Day 1, 2, 7, 8, Fixed Days 1, 2, 14, 15, 28, 29, Early Termination and Last Visit.

  5. Incidence of ECG Evaluations of Potential Clinical Significance

    The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.

    Time frame: Titratrion Day 1 and 7, Fixed dose Day 1, 14, 28, Early Termination

  6. Incidence of Physical Examination Evaluation of Potential Clinical Significance

    The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.

    Time frame: Physical examination was performed at Screening, check-in, and discharge

  7. Mean Change From Baseline to Study Completion in Simpson-Angus Scale (SAS) Total Score

    EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.

    Time frame: End of Titration, Day 15, Day 29, Early Termination and Last visit

  8. Mean Change From Baseline to Study Completion in Barnes Akathisia Global Score

    EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The Barnes Akathisia Rating Scale was an EPS rating scale. The Barnes Akathisia Rating Scale was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).

    Time frame: End of Titration, Day 15, Day 29, Early Termination and Last visit

  9. Mean Change From Baseline to Study Completion in Abnormal Involuntary Movement Scale (AIMS) Rating Score.

    EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The AIMS Scale was an EPS rating scale. The AIMS is a 12 item scale. The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.

    Time frame: End of Titration, Day 15, Day 29, Early Termination and Last visit

  10. Change From Baseline to Study Completion in C-SSRS Score.

    The C-SSRS was one of the primary parameters to measure the safety and tolerability of individual participants. Suicidality was monitored during the trial using the C-SSRS. This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last trial visit.

    Time frame: Baseline, End of Titration, Fixed dose Day 14 and 28, Day 15 and 29, Early Termination, Last Visit

07

Results

Posted Feb 4, 2016
Limitations and caveats
Cohort 3 was not initiated based on the safety/tolerability results from Cohorts 1 and 2.

Participant flow

This was a phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose trial planned in 3 sequential cohorts of elderly participants (70 to 85 years old) with major depressive disorder (MDD). Brexpiprazole was administered as an adjunct treatment to the current antidepressant therapy that the participant received.

Participant flow — Overall Study
MilestoneBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Brexpiprazole-Cohort 3Placebo
Started6705
Completed6504
Not completed0201
Withdrew: Adverse event0100
Withdrew: Physician decision0100
Withdrew: Participant met withdrawal criteria0001

Outcome measures

PrimaryNumber of Participants Who Tolerated Brexpiprazole

Safety and tolerability of brexpiprazole was noted to be primary outcome measure. Brexpiprazole was judged to be tolerated if at least 6 out of 8 (75%) of the participants in a test cohort tolerated the dose after 14 days of QD dosing at the end of the fixed dose phase based on the blinded data. Dose toleration was defined as follows: during the course of the trial, the participants did not experience any moderate or severe adverse events (AEs) or potentially clinically relevant changes from Baseline in laboratory values, vital signs, electrocardiogram (ECG) tracings, Columbia-Suicide Severity Rating Scale (C-SSRS), or extrapyramidal symptom (EPS) ratings, which were assessed as possibly related to the study drug, and would have warranted a dose decrease or discontinuation of the study drug. The safety and tolerability of brexpiprazole was defined by parameters: AEs, laboratory values, vital signs, ECG, C-SSRS, or EPS ratings, the results of each of the parameters reported separately.

Time frame:
45 Days
Reported as:
Number · participants
Number of Participants Who Tolerated Brexpiprazole
participantsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Number of Participants Who Tolerated Brexpiprazole675
PrimaryNumber of AEs Reported.

The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial. AEs were measured throughout the 14-day titration and 28-day fixed dose phase until follow-up (30 \[±2\] days after last dose of study medication).

Time frame:
Throughout the study, up to 119 days
Reported as:
Number · Events
Number of AEs Reported.
EventsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Adverse events12335
Treatment emergent adverse events (TEAEs)663
Serious adverse events000
PrimaryIncidence of Laboratory Values of Potential Clinical Significance

The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.

Time frame:
Titration Day 7, Fixed dose Day 14 and 28 and Last Visit
Reported as:
Number · Participants
Incidence of Laboratory Values of Potential Clinical Significance
ParticipantsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Cholesterol, fasting011
Glucose001
LDL direct, fasting001
Triglycerides, fasting213
Uric acid001
Hematocrit021
Prolactin200
PrimaryIncidence of Vital Signs of Potential Clinical Significance

The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.

Time frame:
Baseline, Titration Day 1, 2, 7, 8, Fixed Days 1, 2, 14, 15, 28, 29, Early Termination and Last Visit.
Reported as:
Number · Participants
Incidence of Vital Signs of Potential Clinical Significance
ParticipantsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Weight increase200
Supine hypotension, decrease100
PrimaryIncidence of ECG Evaluations of Potential Clinical Significance

The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.

Time frame:
Titratrion Day 1 and 7, Fixed dose Day 1, 14, 28, Early Termination
Reported as:
Number · Participants
Incidence of ECG Evaluations of Potential Clinical Significance
ParticipantsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Supraventricular premature beat021
Ventricular premature beat301
Left bundle-branch block001
Myocardial ischemia100
Symmetrical T-wave inversions110
Increase in QTcB132
Increase in QTcF122
PrimaryIncidence of Physical Examination Evaluation of Potential Clinical Significance

The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.

Time frame:
Physical examination was performed at Screening, check-in, and discharge
Reported as:
Number · Participants
Incidence of Physical Examination Evaluation of Potential Clinical Significance
ParticipantsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Incidence of Physical Examination Evaluation of Potential Clinical Significance000
PrimaryMean Change From Baseline to Study Completion in Simpson-Angus Scale (SAS) Total Score

EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.

Time frame:
End of Titration, Day 15, Day 29, Early Termination and Last visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Study Completion in Simpson-Angus Scale (SAS) Total Score
Units on a scaleBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
End of Titration (N= 6, 6, 4)-0.3 ± 0.5-0.5 ± 0.8-1.0 ± 0.8
Day 15 (N= 0, 5, 2)NA ± NA0.2 ± 0.4-1.5 ± 0.7
Day 29 (N=6, 0, 2)-0.3 ± 0.4NA ± NA0.0 ± 0.0
Early Termination (N= 0, 1, 1)NA ± NA-1.0 ± NA0.0 ± NA
Last visit (N= 6, 6, 5)-0.2 ± 0.40.0 ± 0.6-0.6 ± 0.9
PrimaryMean Change From Baseline to Study Completion in Barnes Akathisia Global Score

EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The Barnes Akathisia Rating Scale was an EPS rating scale. The Barnes Akathisia Rating Scale was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).

Time frame:
End of Titration, Day 15, Day 29, Early Termination and Last visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Study Completion in Barnes Akathisia Global Score
Units on a scaleBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
End of Titration (N= 6, 6, 4)-0.2 ± 0.40.0 ± 0.0-0.5 ± 0.6
Day 15 (N= 0, 5, 2)NA ± NA0.0 ± 0.0-0.5 ± 0.7
Day 29 (N= 6, 0, 2)0.0 ± 0.0NA ± NA-0.5 ± 0.7
Early Termination (N= 0, 1, 1)NA ± NA0.0 ± NA0.0 ± NA
Last visit (N= 6, 6, 5)0.0 ± 0.00.0 ± 0.0-0.4 ± 0.5
PrimaryMean Change From Baseline to Study Completion in Abnormal Involuntary Movement Scale (AIMS) Rating Score.

EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The AIMS Scale was an EPS rating scale. The AIMS is a 12 item scale. The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.

Time frame:
End of Titration, Day 15, Day 29, Early Termination and Last visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Study Completion in Abnormal Involuntary Movement Scale (AIMS) Rating Score.
Units on a scaleBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
End of Titration (N= 6, 6, 4)0.0 ± 0.00.2 ± 0.40.0 ± 0.0
Day 15 (N= 0, 5, 2)NA ± NA0.0 ± 0.00.0 ± 0.0
Day 29 (N= 6, 0, 2)0.0 ± 0.0NA ± NA0.0 ± 0.0
Early Termination (N= 0, 1, 1)NA ± NA0.0 ± NA0.0 ± NA
Last Visit (N= 6, 6, 5)0.0 ± 0.00.0 ± 0.00.0 ± 0.0
PrimaryChange From Baseline to Study Completion in C-SSRS Score.

The C-SSRS was one of the primary parameters to measure the safety and tolerability of individual participants. Suicidality was monitored during the trial using the C-SSRS. This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last trial visit.

Time frame:
Baseline, End of Titration, Fixed dose Day 14 and 28, Day 15 and 29, Early Termination, Last Visit
Reported as:
Number · Participants
Change From Baseline to Study Completion in C-SSRS Score.
ParticipantsBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
Suicidality000
Suicidal behaviour000
Suicidal ideation000

Adverse events

Collected over AEs were captured for all participants from the signing of the informed consent and were measured throughout the 14-day titration period, 28-day fixed dose period until follow-up (30 [±2] days after last dose of study medication).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole-Cohort 1—0/6 (0%)6/6 (100%)
Brexpiprazole-Cohort 2—0/6 (0%)6/6 (100%)
Placebo—0/5 (0%)1/5 (20%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventBrexpiprazole-Cohort 1Brexpiprazole-Cohort 2Placebo
DizzinessNervous system disorders0/63/60/5
DyspepsiaGastrointestinal disorders0/62/60/5
NauseaGastrointestinal disorders0/62/60/5
Weight increasedInvestigations2/60/60/5
PollakiuriaRenal and urinary disorders2/60/60/5
HeadacheNervous system disorders1/60/61/5
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/60/61/5
Eye pruritisEye disorders0/60/61/5
Dry eyeEye disorders0/60/61/5
Atrioventricular block first degreeCardiac disorders1/61/60/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole-Cohort 1Brexpiprazole-Cohort 2PlaceboTotal
Mean73.2 ± 4.076.0 ± 5.372.6 ± 1.574.1 ± 4.2
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole-Cohort 1Brexpiprazole-Cohort 2PlaceboTotal
Female45413
Male2215
08

Study locations

4 sites
  • Accurate Clinical Trials
    Kissimmee, Florida, United States
  • Miami Jewish Health System
    Miami, Florida, United States
  • St. Louis Clinical Trials
    St. Louis, Missouri, United States
  • CRI Lifetree- Philadelphia Research Center
    Philadelphia, Pennsylvania, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2012
First posted
Aug 22, 2012
Start
Jul 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Feb 4, 2016
Last update
Feb 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01670279
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 22, 2012
Start date
Jul 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Feb 4, 2016
Last update
Feb 4, 2016

Study contacts

James M. Youakim, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion